Abstracts tagged "Lung Disease"

Abstract Number: 2053 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Intermittent Intra-Venous Cyclophosphamide and Cyclosporin A Combination Therapy For Rapidly Progressive Interstitial Lung Disease With Dermatomyositis Associated With Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody Titer
Noriko Sasaki¹, Shinji Sato¹, Shinichi Nogi¹, Naofumi Chinen², Kiri Honda¹, Eiko Saito¹, Chiho Yamada² and Yasuo Suzuki², ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) autoantibody is present specifically in patients with dermatomyositis (DM), especially those with few or no muscle manifestations (clinically amyopathic…
Abstract Number: 922 • 2013 ACR/ARHP Annual Meeting
Role Of B Cells and/Or Autoantibodies In Pulmonary Manifestations Of Inflammatory Arthritis
Lisa K. Peterson¹, Jeremy Sokolove², Paul Jedlicka³, Lauren J. Lahey⁴, William H. Robinson⁵ and Leonard L. Dragone⁶, ¹Pediatrics, National Jewish Health, Denver, CO, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Pathology, University of Colorado Denver, Aurora, CO, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁵VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁶Dept of Pediatrics, National Jewish Health, Denver, CO
Background/Purpose: RA is a systemic condition affecting approximately 1% of the general population leading to progressive arthritis and extra-articular manifestations (ExRA), including interstitial lung disease…
Abstract Number: 926 • 2013 ACR/ARHP Annual Meeting
Autoantibodies to the Th/To Complex Are the Most Common Antibodies in Systemic Sclerosis (SSc) Patients Without Other Autoantibodies
Michael Mahler¹, Jason Y.F. Chan², Edward K.L. Chan³, Minoru Satoh², Marie Hudson⁴, Murray Baron⁵, James Wick⁶ and Marvin J. Fritzler⁷, ¹Research, INOVA Diagnostics, San Diego, CA, ²Medicine, University of Florida, Gainesville, FL, ³Oral Biology, University of Florida, Gainesville, FL, ⁴Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁶Department of medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Antinuclear antibodies (ANA) play an important role in the diagnosis of systemic sclerosis (SSc) being present in about 80-90% of the patients. In the…
Abstract Number: 697 • 2013 ACR/ARHP Annual Meeting
Longitudinal Assessment Of Pulmonary Function In 304 Norwegian Patients With Systemic Sclerosis
Anna-Maria Hoffmann-Vold¹, Torhild Garen², Oyvind Midtvedt¹, May-Brit Lund³, Jan Tore Gran¹ and Øyvind Molberg⁴, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Pulmonary Unit, Oslo University Hospital, Rikshopitalet, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: The purpose of this study was to asses sequential pulmonary function measurements (forced vital capacity [FVC] % predicted) in a large systemic sclerosis (SSc)…
Abstract Number: 666 • 2013 ACR/ARHP Annual Meeting
Involvement Of TCR Vdelta1⁺ NKT Cells In Systemic Sclerosis: Association With Interstitial Pneumonia
Seiji Segawa¹, Daisuke Goto², Masanobu Horikoshi², Yuya Kondo³, Naoto Umeda², Shinya Hagiwara², Masahiro Yokosawa⁴, Tomoya Hirota³, Haruka Miki¹, Hiroto Tsuboi³, Hiroshi Ogishima², Takeshi Suzuki⁴, Isao Matsumoto⁵ and Takayuki Sumida³, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan, ²Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁵Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interstitial pneumonia (IP) is one of the critical complications in patients with several autoimmune diseases. However, the exact mechanism of IP remains elusive. Recently,…
Abstract Number: 675 • 2013 ACR/ARHP Annual Meeting
Impact Of Male Sex On Survival In Systemic Sclerosis
Haseena Hussein¹, Peter Lee², Cathy Chau³ and Sindhu R. Johnson⁴, ¹Medicine, Toronto Scleroderma Research Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ³Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) has a female predominance with a female-to-male ratio of 3:1. Sex differences have been seen in many autoimmune diseases; however, little…
Abstract Number: 648 • 2013 ACR/ARHP Annual Meeting
A Possible Contribution of Inducible Costimulator to the Development of Skin Sclerosis and Interstitial Lung Disease in Systemic Sclerosis
Koichi Yanaba¹, Yoshihide Asano² and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous disorder characterized by excessive fibrosis and microvascular damage of the skin and various internal organs. Cutaneous mononuclear cell…
Abstract Number: 2902 • 2013 ACR/ARHP Annual Meeting
Key Roles For Interferon and Macrophage Activation In Progressive Lung Fibrosis Associated With Systemic Sclerosis
Romy Christmann¹, Giuseppina Stifano², Claudia Borges³, Carlos Carvalho⁴, Ronaldo Kairalla⁴, Edwin R. Parra⁵, Avrum Spira⁶, Robert W. Simms¹, Percival Sampaio-Barros⁷, Vera L. Capelozzi⁵ and Robert Lafyatis¹, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University Medical Center, Boston, MA, ³Rheumatology, CEUMA University, Sao Luis do Maranhao, Brazil, ⁴Pulmonology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁵Pathology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁶Computational Biomedicine, Boston University School of Medicine, Boston, MA, ⁷Rheumatology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Background/Purpose: Interstitial lung disease associate with Systemic Sclerosis(SSc-ILD) is one of the leading causes of mortality. We analyzed the gene expression of lung tissue in…
Abstract Number: 651 • 2013 ACR/ARHP Annual Meeting
Growth Differentation Factor-15, a Marker Of lung disease In Systemic Sclerosis, Is Involved In Fibrosis Development But Does Not Impair Fibrosis Development
Stijn Lambrecht¹, Vanessa Smith², Katelijne De wilde³, Julie Coudenys⁴, Filip De Keyser² and Dirk Elewaut⁵, ¹Dept of Rheumatology, Laboratory for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Deptartment of Rheumatology, Ghent University, Ghent, Belgium, ⁴Dept of Rheumatology, Ghent University, Ghent, Belgium, ⁵Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose: It is generally known that members of the TGF-β superfamily are involved in the regulation of connective tissue biology in systemic sclerosis (SSc). Growth…
Abstract Number: 2685 • 2013 ACR/ARHP Annual Meeting
Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive Antibodies Are Associated With Radiographic Interstitial Lung Disease In Rheumatoid Arthritis, An Effect Potentiated By Smoking
Jon T. Giles¹, Erika Darrah², Sonye K. Danoff³, Cheilonda Johnson⁴, Felipe Andrade⁵, Antony Rosen² and Joan M. Bathon⁶, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ⁴Medicine/Pulmonology, Johns Hopkins University, Baltimore, MD, ⁵Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Columbia University, New York, NY
Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are implicated in the pathogenesis of interstitial lung disease (ILD) in rheumatoid arthritis (RA). Citrullinated proteins and the enzymes…
Abstract Number: 423 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers For The Development Of Rheumatoid Arthritis Related Interstitial Lung Disease
Elena Nikiphorou¹, Esther Chan², Vadivelu Saravanan², Julie Dawson³, Navtej Sathi⁴, Felix Woodhead⁵, Mohamed Nisar⁶, Subhashini Arthanari⁶, Yasmeen Ahmad⁷, Adam Young⁸ and Clive Kelly², ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom, ³Rheumatology, St Helens Hospital, St Helens, United Kingdom, ⁴Rheumatology, Wrightington Hospital, Wigan, United Kingdom, ⁵Respiratory, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ⁶Rheumatology, Burton Hospital, Burton-on-Trent, United Kingdom, ⁷Department of Rheumatology, Peter Maddison Research Centre, Bangor, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: Interstitial Lung Disease (ILD) is the commonest manifestation of lung disease in Rheumatoid Arthritis (RA) and the only complication reported to be increasing in…
Abstract Number: 2573 • 2013 ACR/ARHP Annual Meeting
The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis
Mesias Pedroza¹, Sarah To¹, Anuh T. George¹, David J. Tweardy² and Sandeep K. Agarwal¹, ¹Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibrosis is the accumulation of excessive extra-cellular matrix in tissues, leading to tissue damage. In systemic sclerosis, the trigger is postulated to be an…
Abstract Number: 412 • 2013 ACR/ARHP Annual Meeting
Clinical Characterization Of Extensive Interstitial Lung Disease In Rheumatoid Arthritis Patients
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Yamasaki Clinic, Yokohama, Japan

Background/Purpose: To investigate clinical characteristics of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients, and to analyze whether high resolutional CT (HRCT) can predict…
Abstract Number: 2574 • 2013 ACR/ARHP Annual Meeting
Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease
Elizabeth Volkmann¹, Rajan Saggar², Bryant Torres¹, Lynne Yoder², Robert Elashoff³, Rajeev Saggar⁴, Harsh Agrawal¹, Nabeel Borazan⁵, Sarah Thomas¹ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomath, University of California, Los Angeles, Los Angeles, CA, ⁴Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ⁵Medicine, Rheumatology UCLA, Los Angeles, CA
Background/Purpose: The leading causes of death in systemic sclerosis (SSc) are pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Use of PAH therapy in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].